Status
Conditions
Treatments
About
The purpose of this study is to determine the effects of Apelin on the lung circulation. The investigators hypothesise that Apelin will relax the lung blood vessels and improve the pumping ability of the heart.
Full description
Apelin is an endogenous peptide with physiological actions in the cardiovascular system and is abundantly expressed in the pulmonary vasculature. Pre-clinical models and preliminary clinical data indicate that Apelin deficiency may mediate or contribute to the pathogenesis of pulmonary hypertension and heart failure. Apelin causes peripheral vasodilatation and increased cardiac contractility. The investigators will determine the effects of Apelin on the pulmonary circulation in 3 groups; healthy control, people with pulmonary arterial hypertension and people with pulmonary hypertension due to heart failure. Each subject will receive both Apelin infusion and saline placebo infusion in a crossover design. The infusions will be given in a random order which the subject and the investigator will be blinded to. The investigators hypothesise that Apelin will have more marked pulmonary haemodynamic effects than that observed in the systemic circulation. Moreover, the investigators propose that Apelin will have a marked vasodilatory effect on the human pulmonary vasculature and reduce pulmonary vascular resistance in patients with pulmonary arterial hypertension or pulmonary hypertension due to left heart disease.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
PULMONARY ARTERIAL HYPERTENSION
Inclusion Criteria:
Exclusion Criteria:
HEART FAILURE
Inclusion Criteria:
HEALTHY VOLUNTEERS
Inclusion Criteria:
Exclusion Criteria:
ALL SUBJECTS
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
63 participants in 2 patient groups
Loading...
Central trial contact
Lauren Brash, MBChB; Andrew J Peacock, BSc MPhil MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal